Delivery of photosensitisers and light through mucus: Investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection

Journal of Controlled Release

Volumn 117, Issue 2, 2007, Pages 217-226

  Donnelly, Ryan F ^a   McCarron, Paul A ^a   Cassidy, Corona M ^a   Elborn, J Stuart ^a   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cystic fibrosis; Diffusion; Mucus; Photodynamic; Pseudomonas aeruginosa

Indexed keywords

CYSTIC FIBROSIS (CF); MUCUS; PHOTOSENSITISERS; PSEUDOMONAS AERUGINOSA;

BIOFILMS; DISEASES; PATIENT MONITORING; PHOTOSENSITIVITY;

PHOTODYNAMIC THERAPY;

MESO TETRAKIS(N METHYL 4 PYRIDYL)PORPHINE TETRA TOSYLATE; PHOTOSENSITIZING AGENT; TOLONIUM CHLORIDE; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPLANKTON; BACTERIUM ISOLATE; BIOFILM; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; LUNG INFECTION; MUCUS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RED LIGHT;

CYSTIC FIBROSIS; DIFFUSION; HUMANS; LIGHT; MICROBIAL VIABILITY; MUCUS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPECTROPHOTOMETRY; SPECTROPHOTOMETRY, ULTRAVIOLET; TOLONIUM CHLORIDE;

EID: 33846545579     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.11.010     Document Type: Article

References (46)

1. Boucher R.C. An overview of the pathogenesis of cystic fibrosis lung disease. Adv. Drug Deliv. Rev. 54 (2002) 1359-1371
2. Dodge J.A., Morison S., Lewis P.A., Coles E.C., Geddes D., Russell G., Littlewood J.M., and Scott M.T. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch. Dis. Child. 77 (1997) 493-496
3. Whitehead A. Treating adults with cystic fibrosis. Pharm. J. 266 (2001) 508-510
4. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Doring G., and von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr. Pulmonol. 25 (1998) 88-92
5. Fegan M., Francis P., Hayward A.C., Davis G.H., and Fuerst J.A. Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis. J. Clin. Microbiol. 28 (1990) 1143-1146
6. Lam J., Chan R., Lam K., and Costerton J.W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28 (1980) 546-556
7. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., and Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 (2000) 762-764
8. Shigeta M., Tanaka G., Komatsuzawa H., Sugai M., Suginaka H., and Usui T. Permeation of antimicrobial agents through Pseudomonas aeruginosa biofilms: a simple method. Chemotherapy 43 (1997) 340-345
9. Anwar H., Strap J.L., and Costerton J.W. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob. Agents Chemother. 36 (1992) 1347-1351
10. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292 (2002) 107-113
11. Gilligan P.H. Microbiology of airway disease in patients with cystic fibrosis. Clin. Microbiol. Rev. 4 (1991) 35-51
12. Spencer H., and Jaffe A. Newer therapies for cystic fibrosis. Curr. Paediatr. 13 (2003) 259-263
13. Boucher R.C. New concepts of pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23 (2004) 146-158
14. Høiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J. Cystic Fibrosis 1 (2002) 249-254
15. Donnelly R.F., McCarron P.A., and Woolfson A.D. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem. Photobiol. 81 (2005) 750-767
16. Moan J., and Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23 (2003) 3591-3600
17. Jori G., and Brown S.B. Photosensitized inactivation of microorganisms. Photochem. Photobiol. Sci. 3 (2004) 403-405
18. Wainwright M., and Crossley K.B. Photosensitising agents-circumventing resistance and breaking down biofilms: a review. Int. Biodeterior. Biodegrad. 53 (2004) 119-126
19. Wainwright M., Phoenix D.A., Marland J., Wareing D.R.A., and Bolton F.J. A study of photobactericidal activity in the phenothiazinium series. FEMS Immunol. Med. Microbiol. 19 (1997) 75-80
20. Wainwright M., Phoenix D.A., Nickson P.B., and Morton G. The use of new methylene blue in Pseudomonas aeruginosa biofilm destruction. Biofouling 18 (2002) 247-249
21. Usacheva M.N., Teichert M.C., and Biel M.A. The role of the methylene blue and toluidine blue monomers and dimers in the photoinactivation of bacteria. J. Photochem. Photobiol., B Biol. 71 (2003) 87-98
22. Szpakowska M., Reiss J., Graczyk A., Szmigielski S., Lasocki K., and Grzybowski J. Susceptibility of Pseudomonas aeruginosa to a photodynamic effect of the arginine hematoporphyrin derivative. Int. J. Antimicrob. Agents 8 (1997) 23-27
23. Szpakowska M., Lasocki K., Grzybowski J., and Graczyk A. Photodynamic activity of the haematoporphyrin derivative with rutin and arginine substituents (GpD-Rut2-Arg2) against Staphylococcus aureus and Pseudomonas aeruginosa. Pharmacol. Res. 44 (2001) 243-246
24. Minnock A., Vernon D.I., Schofield J., Griffiths J., Parish J.H., and Brown S.B. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both Gram-negative and Gram-positive bacteria. J. Photochem. Photobiol., B Biol. 32 (1996) 159-164
25. McCarron P.A., Donnelly R.F., Zawislak A., Woolfson A.D., Price J.H., and McClelland R. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions. Int. J. Pharm. 293 (2005) 11-23
26. Donnelly R.F., McCarron P.A., Lightowler J.M., and Woolfson A.D. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J. Contemp. Relig. 103 (2005) 381-392
27. R.F. Donnelly, P.A. McCarron, M.M. Tunney, A.D.Woolfson, Potential of photodynamic therapy in treatment of fungal infections of the mouth. Design and characterisation of a mucoadhesive patch containing toluidine blue O, J. Photochem. Photobiol. B: Biol. 86, 59-69.
28. Sriramulu D.D., Lunsdorf H., Lam J.S., and Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol. 54 (2005) 667-676
29. Giwercman B., Jensen E.T., Hoiby N., Kharazmi A., and Costerton J.W. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob. Agents Chemother. 35 (1991) 1008-1010
30. Komerik N., Wilson M., and Poole S. The effect of photodynamic action on two virulence factors of Gram-negative bacteria. Photochem. Photobiol. 72 (2000) 676-680
31. Khanvilkar K., Donovan M., and Flannagan D. Drug transfer through mucus. Adv. Drug Deliv. Rev. 48 (2001) 173-193
32. Gannon M.J., and Brown S.B. Photodynamic therapy and its applications in gynaecology. Br. J. Obstet. Gynaecol. 106 (1999) 1246-1254
33. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect. 5 (2003) 1213-1219
34. Meso-tetra (N-methyl-4-pyridyl) Porphine Tetra Tosylate (TMP) Product Data Sheet (2004), Frontier Scientific Europe Ltd, Carnforth, Lancashire, UK
35. Lee C.F., Lee C.J., Chen C.T., and Huang C.T. δ-Aminolaevulinic acid mediated photodynamic antimicrobial chemotherapy on Pseudomonas aeruginosa planktonic and biofilm cultures. J. Photochem. Photobiol., B Biol. 1-2 (2004) 21-25
36. Brooun A., Liu S., and Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 44 (2000) 640-646
37. Borriello G., Werner E., Roe F., Kim A.M., Ehrlich G.D., and Stewart P.S. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother. 48 (2004) 2659-2664
38. Field T.R., White A., Elborn J.S., and Tunney M.M. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 677-687
39. Bhatti M., MacRobert A., Meghji S., Henderson B., and Wilson M. Effect of dosimetric and physiological factors on the lethal photosensitization of Porphyromonas gingivalis in vitro. Photochem. Photobiol. 65 (1997) 1026-1031
40. Wilson M., and Pratten J. Lethal photosensitization of Staphylococcus aureus in vitro. Effect of growth phase, serum, and pre-irradiation time. Lasers Surg. Med. 16 (1995) 272-276
41. Nitzan Y., Balzam-Sudakevitz A., and Ashkenazi H. Eradication of Acinetobacter baumannii by photosensitized agents in vitro. J. Photochem. Photobiol., B Biol. 42 (1998) 211-218
42. Lambrechts S., Aalders M., Verbraak F., Lagerberg J., Dankert J., and Schuitmaker J. Effect of albumin on the photodynamic inactivation of microorganisms by cationic porphyrin. Photochem. Photobiol. 79 (2005) 51-57
43. Kömerik N., and Wilson M. Factors influencing the susceptibility of Gram-negative bacteria to toluidine blue O-mediated lethal photosensitization. J. Appl. Microbiol. 92 (2002) 618-623
44. Baumgartner R., Huber R.M., Schultz H., Stepp H., Rick K., Gamarra F., Leberig A., and Roth C. Inhalation of 5-aminolevulinic acid: a new technique for fluorescence detection of early stage lung cancer. J. Photochem. Photobiol., B Biol. 36 (1996) 169-174
45. Kato H. Photodynamic therapy for lung cancer-a review of 19 years' experience. J. Photochem. Photobiol., B Biol. 42 (1998) 96-99
46. Demidova TN., and Hamblin M.R. Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob. Agents Chemother. 49 (2005) 2329-2335